Radiopharm Theranostics (ASX:RAD) to Spotlight Oncology Pipeline at NWR Conference

1 min read | March 19, 2026 12:38 PM AEDT | By Sonal Goyal

Google News:

Radiopharm Theranostics (ASX:RAD) to Spotlight Oncology Pipeline at NWR Conference — Image source: Company Update

Recent News

Why Are Lynas Rare Earths (ASX:LYC), Paladin Energy (ASX:PDN) and Elev...

Why Did Coles (ASX:COL) Rise While Mining Stocks Dragged the ASX Lower...

Why Did AMP (ASX:AMP) Lead the ASX 200's Top Performers Today?

Why Are Lynas Rare Earths (ASX:LYC), Paladin Energy (ASX:PDN) and Elev...

Make Kalkine Media
My Trusted Source

Highlights

Radiopharm Theranostics will participate in the NWR Virtual Healthcare Conference to showcase its oncology-focused innovations.

CEO & Managing Director Riccardo Canevari will outline the company’s strategy and oncology pipeline.

The company is advancing targeted radiopharmaceuticals for cancers with limited treatment options.

Clinical-stage biopharmaceutical company Radiopharm Theranostics (ASX:RAD) (NASDAQ:RADX) has announced its participation in the upcoming NWR Virtual Healthcare Conference, where it will showcase progress in its oncology-focused radiopharmaceutical portfolio.

CEO and Managing Director of RAD Riccardo Canevari is scheduled to present on Wednesday, 25 March 2026, at 8:30 a.m. AEDT. The presentation is expected to provide insights into the company’s strategic direction and its expanding pipeline of targeted cancer therapies.

RAD is focused on advancing radiopharmaceutical products to diagnose and treat cancers that currently have limited effective options. Its platform includes a mix of peptides, small molecules, and antibodies designed to deliver highly targeted precision oncology solutions.

Listed on both the ASX and NASDAQ (RADX), Radiopharm continues to strengthen its position in the radiotherapeutics space by leveraging its differentiated platforms to advance next-generation cancer treatments.

RAD shares were trading at AUD 0.021 per share at the time of writing on 19 March 2026.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.